Experimental drug PRL3-ZUMAB shows promise in Hard-to-Treat cancers
NCT ID NCT04118114
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also looked for biological markers to predict who might benefit most. The goal was to find a new option for patients with few choices left.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Center Singapore
Singapore, 169690, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can your own immune cells beat advanced cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Could a vaccine help fight Hard-to-Treat cancers?